ATE477813T1 - Erythropoietin-lösungszubereitung, stabilisiert mit leucin oder glutaminsäure - Google Patents

Erythropoietin-lösungszubereitung, stabilisiert mit leucin oder glutaminsäure

Info

Publication number
ATE477813T1
ATE477813T1 AT06012448T AT06012448T ATE477813T1 AT E477813 T1 ATE477813 T1 AT E477813T1 AT 06012448 T AT06012448 T AT 06012448T AT 06012448 T AT06012448 T AT 06012448T AT E477813 T1 ATE477813 T1 AT E477813T1
Authority
AT
Austria
Prior art keywords
solution preparation
leucine
glutamic acid
erythropoietin solution
preparation stabilized
Prior art date
Application number
AT06012448T
Other languages
English (en)
Inventor
Tadao Yamazaki
Toshiari Morita
Hiroshi Nagai
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26466124&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE477813(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE477813T1 publication Critical patent/ATE477813T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT06012448T 1996-04-26 1997-04-25 Erythropoietin-lösungszubereitung, stabilisiert mit leucin oder glutaminsäure ATE477813T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP13122696 1996-04-26
JP30395696 1996-10-30

Publications (1)

Publication Number Publication Date
ATE477813T1 true ATE477813T1 (de) 2010-09-15

Family

ID=26466124

Family Applications (2)

Application Number Title Priority Date Filing Date
AT97919693T ATE330622T1 (de) 1996-04-26 1997-04-25 Mit aminosäuren stabilisierte erythropoietinlösung
AT06012448T ATE477813T1 (de) 1996-04-26 1997-04-25 Erythropoietin-lösungszubereitung, stabilisiert mit leucin oder glutaminsäure

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT97919693T ATE330622T1 (de) 1996-04-26 1997-04-25 Mit aminosäuren stabilisierte erythropoietinlösung

Country Status (10)

Country Link
US (4) US6120761A (de)
EP (2) EP1712237B1 (de)
JP (3) JP3068033B2 (de)
KR (2) KR20040004414A (de)
AT (2) ATE330622T1 (de)
AU (1) AU722300B2 (de)
DE (2) DE69736177T2 (de)
ES (1) ES2267140T3 (de)
TW (2) TW518219B (de)
WO (1) WO1997040850A1 (de)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW518219B (en) * 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
JP2011025068A (ja) * 1999-02-22 2011-02-10 Chugai Pharmaceut Co Ltd プレフィルドシリンジタンパク質溶液製剤
JP2007204498A (ja) * 1999-03-01 2007-08-16 Chugai Pharmaceut Co Ltd 長期安定化製剤
ATE401908T1 (de) * 1999-04-09 2008-08-15 Ortho Mcneil Pharm Inc Pharmazeutische zusammensetzungen von erythropoietin
EP1232753B1 (de) * 1999-09-08 2008-03-19 Chugai Seiyaku Kabushiki Kaisha Stabile proteinlösung abgefüllt in einem behältnis aus hydrophobem harz und eine methode zur stabilisierung derselben
JP5271481B2 (ja) * 1999-09-08 2013-08-21 中外製薬株式会社 タンパク質溶液製剤およびその安定化方法
GB9930882D0 (en) * 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
AU2001236005A1 (en) * 2000-02-29 2001-09-12 Chugai Seiyaku Kabushiki Kaisha Preparations stabilized over long time
AU2005225151B2 (en) * 2000-05-15 2008-05-29 F. Hoffmann-La Roche Ag New pharmaceutical composition
JP3967594B2 (ja) † 2000-05-15 2007-08-29 エフ．ホフマン−ラ ロシュ アーゲー 新しい薬剤組成物
JP5490972B2 (ja) * 2000-08-04 2014-05-14 中外製薬株式会社 タンパク質注射製剤
JP4147234B2 (ja) * 2004-09-27 2008-09-10 キヤノン株式会社 吐出用液体、吐出方法、カートリッジ及び吐出装置
JP4340062B2 (ja) 2000-10-12 2009-10-07 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
CA2431964C (en) 2000-12-20 2013-09-10 F. Hoffmann-La Roche Ag Conjugates of erythropoietin (pep) with polyethylene glycol (peg)
EP1382964A4 (de) * 2001-04-17 2009-06-10 Chugai Pharmaceutical Co Ltd Verfahren zur tensid-quantifizierung
US7682608B2 (en) 2001-08-29 2010-03-23 Chugai Seiyaku Kabushiki Kaisha Stabilized preparations containing antibody
US7741285B2 (en) * 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
US7842668B1 (en) 2001-11-13 2010-11-30 Genentech, Inc. Apo-2 ligand/trail formulations
EP1450847B1 (de) * 2001-11-13 2010-09-29 Genentech, Inc. Zusammensetzungen basierend auf APO2-Ligand/ TRAIL und ihre Verwendung
RU2357751C2 (ru) 2001-12-21 2009-06-10 Ново Нордиск Хелт Кэр Аг Жидкая композиция полипептидов фактора vii
SI1478394T1 (sl) 2002-02-27 2008-12-31 Immunex Corp STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM
BRPI0311959B8 (pt) 2002-06-21 2021-05-25 Novo Nordisk Healthcare Ag composição, métodos para preparar um polipeptídeo estável do fator vii, e para tratar uma síndrome responsiva do fator vii, e, uso do polipeptídeo do fator vii
WO2004007520A2 (en) * 2002-07-12 2004-01-22 Medarex, Inc. Methods and compositions for preventing oxidative degradation of proteins
SI21257A (sl) * 2002-07-17 2004-02-29 LEK farmacevtska dru�ba d.d. Stabilni farmacevtski pripravek, ki vsebuje eritropoietin
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
ZA200507486B (en) 2003-03-07 2007-03-28 Astellas Pharma Inc Nitrogenous heterocyclic derivative having 2,6-disubstituted styryl
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
US20040198663A1 (en) * 2003-04-04 2004-10-07 Baker John E. Method of treating cardiac ischemia by using erythropoietin
AU2004229335C1 (en) * 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
RU2364609C2 (ru) 2003-05-23 2009-08-20 Ново Нордиск Хелт Кэр Аг Стабилизация белка в растворе
ATE553747T1 (de) 2003-06-10 2012-05-15 Lg Life Sciences Ltd Stabile wässrige lösung von human-erythropoietin, die kein serumalbumin enthält
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
KR100560697B1 (ko) * 2003-08-06 2006-03-16 씨제이 주식회사 알부민을 함유하지 않는 에리스로포이에틴 제제
AU2004264282B2 (en) 2003-08-14 2010-10-14 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of Factor VII polypeptides
US7141544B2 (en) * 2003-10-10 2006-11-28 Baxter International, Inc. Stabilization of pharmaceutical protein formulations with small peptides
EP1537876A1 (de) * 2003-12-01 2005-06-08 BioGeneriX AG Formulierung einer Erythropoietin Lösung
KR20150138427A (ko) 2003-12-19 2015-12-09 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｖｉｉ 폴리펩티드의 안정화된 조성물
DE202004020676U1 (de) * 2004-03-10 2005-11-10 Bioceuticals Arzneimittel Ag Erythropoietin-Flüssigformulierung
US20050282751A1 (en) * 2004-03-19 2005-12-22 Ajinomoto Co., Inc. Therapeutic agent for renal anemia
US20060099567A1 (en) * 2004-04-08 2006-05-11 Biomatrica, Inc. Integration of sample storage and sample management for life science
AU2005245338B2 (en) 2004-04-08 2011-11-17 Biomatrica, Inc. Integration of sample storage and sample management for life science
KR20070008645A (ko) 2004-05-04 2007-01-17 노보 노르디스크 헬스 케어 악티엔게젤샤프트 폴리펩티드의 ｏ-연결된 단백당형 및 그들의 제조 방법
US20060029551A1 (en) * 2004-08-05 2006-02-09 Kui Liu Stable particle formulations of erythropoietin receptor agonists
US7772182B2 (en) 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JP4147235B2 (ja) * 2004-09-27 2008-09-10 キヤノン株式会社 吐出用液体、吐出方法、液滴化方法、液体吐出カートリッジ及び吐出装置
MX2007004302A (es) * 2004-10-12 2007-06-07 Applied Research Systems Inhibidores de pi3 cinasa gamma para el tratamiento de anemia.
MY139088A (en) * 2005-02-21 2009-08-28 Lg Life Sciences Ltd Sustained release composition of protein drug
KR20080003929A (ko) * 2005-04-26 2008-01-08 아지노모토 가부시키가이샤 골수 적혈구 전구 세포 분화 촉진제
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
ATE501248T1 (de) * 2005-07-02 2011-03-15 Arecor Ltd Stabile wässrige systeme mit proteinen
GB2433425B (en) * 2005-12-23 2010-11-17 Cassidy Brothers Plc Improvements relating to vacuum cleaners
EP1997505A4 (de) * 2006-03-22 2013-02-13 Chugai Pharmaceutical Co Ltd Zubereitung einer erythropoetinlösung
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (de) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Zusammensetzungen von DPP-IV-Inhibitoren
CN102838599A (zh) 2006-05-04 2012-12-26 贝林格尔.英格海姆国际有限公司 多晶型
AU2007255717B2 (en) 2006-06-07 2013-07-11 Chugai Seiyaku Kabushiki Kaisha Treatment of ischemic disease using erythropoietin
WO2008019214A1 (en) 2006-08-04 2008-02-14 Prolong Pharmaceuticals, Inc. Modified erythropoietin
CA2661054A1 (en) 2006-08-22 2008-02-28 Chugai Seiyaku Kabushiki Kaisha Prophylactic and/or therapeutic agents for peripheral neuropathy
KR100784134B1 (ko) * 2006-10-09 2007-12-12 주식회사 대웅 상피세포성장인자를 함유하는 안정한 구내염 치료용 액상조성물
CN101610782A (zh) * 2007-01-10 2009-12-23 爱迪生药物公司 使用具有促红细胞生成素或血小板生成素活性的化合物治疗呼吸链紊乱
AR065613A1 (es) 2007-03-09 2009-06-17 Chugai Pharmaceutical Co Ltd Agentes de proteccion para organos transplantados
WO2009009210A2 (en) * 2007-04-24 2009-01-15 Biomatrica, Inc. Sample storage for life science
CL2008002053A1 (es) * 2007-07-17 2009-05-22 Hoffmann La Roche Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion.
CL2008002054A1 (es) * 2007-07-17 2009-05-29 Hoffmann La Roche Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico.
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
WO2009133408A2 (en) 2008-05-01 2009-11-05 Arecor Limited Protein formulation
CA2724841A1 (en) * 2008-05-22 2009-11-26 Edison Pharmaceuticals, Inc. Treatment of mitochondrial diseases with an erythropoietin mimetic
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
BRPI1006519A2 (pt) 2009-03-06 2016-08-09 Genentech Inc formulação de anticorpos
EP2430195B1 (de) * 2009-05-11 2019-01-23 Biomatrica, INC. Zusammensetzungen und verfahren zur lagerung biologischer proben
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
US8829163B2 (en) 2010-01-19 2014-09-09 Hanmi Science Co., Ltd Liquid formulations for long-acting erythropoietin conjugate
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
RS59830B1 (sr) 2010-03-01 2020-02-28 Bayer Healthcare Llc Optimizovana monoklonska antitela protiv inhibitora puta faktora tkiva (tfpi)
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
WO2012018639A2 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
WO2012018638A2 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
JP5887893B2 (ja) * 2010-12-10 2016-03-16 大正製薬株式会社 内服液剤
AU2012345768B2 (en) 2011-11-30 2016-05-12 Kindeva Drug Delivery L.P. Microneedle device having a peptide therapeutic agent and an amino acid, methods of making and using the same
EP3685839A1 (de) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin zur verwendung in der behandlung von albuminuria und nierenbedingten erkrankungen
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
EP3249054A1 (de) 2012-12-20 2017-11-29 Biomatrica, INC. Formulierungen und verfahren zur stabilisierung von pcr-reagenzien
RS67458B1 (sr) 2014-03-28 2025-12-31 Univ Duke Lečenje kancera dojke pozitivnog na receptor estrogena upotrebom selektivnih modulatora receptora estrogena
WO2015150930A1 (en) 2014-03-29 2015-10-08 Intas Pharmaceuticals Ltd. Liquid pharmaceutical composition of conjugated erythropoietin
WO2015191632A1 (en) 2014-06-10 2015-12-17 Biomatrica, Inc. Stabilization of thrombocytes at ambient temperatures
TWI873632B (zh) 2015-02-27 2025-02-21 日商中外製藥股份有限公司 Il-6受體抗體用於製備醫藥組成物的用途
KR102676629B1 (ko) 2015-04-29 2024-06-18 래디어스 파마슈티컬스, 인코포레이티드 암을 치료하는 방법
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
EP3380487B1 (de) 2015-11-23 2020-09-02 Bristol-Myers Squibb Company Additivsysteme zur verwendung in der proteinpegylierung
KR102589056B1 (ko) 2015-12-08 2023-10-12 바이오매트리카 인코포레이티드 적혈구 침강 속도의 감소
IL285190B (en) * 2016-05-27 2022-07-01 Galderma Holding SA A liquid neurotoxin preparation stabilized by tryptophan or tyrosine
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
ES3064802T3 (en) 2016-10-21 2026-04-29 Amgen Inc Pharmaceutical formulations and methods of making the same
KR102881465B1 (ko) 2017-01-05 2025-11-04 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US11110063B2 (en) 2017-08-25 2021-09-07 MAIA Pharmaceuticals, Inc. Storage stable sincalide formulations
CN112423844B (zh) 2018-07-04 2024-08-13 雷迪厄斯制药公司 Rad1901-2hcl的多晶型形式
JOP20210218A1 (ar) 2019-02-12 2023-01-30 Radius Pharmaceuticals Inc عمليات ومركبات
TWI872251B (zh) 2020-05-29 2025-02-11 日商中外製藥股份有限公司 含有抗體製劑

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
JPH0669960B2 (ja) * 1985-11-22 1994-09-07 エーザイ株式会社 水溶性を増加したｔＰＡ含有医薬組成物
JP2577744B2 (ja) * 1986-07-18 1997-02-05 中外製薬株式会社 安定な顆粒球コロニ−刺激因子含有製剤
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
JP2708749B2 (ja) * 1987-08-10 1998-02-04 エーザイ株式会社 修飾型ｔＰＡ含有注射用組成物
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
JP2844351B2 (ja) * 1989-07-13 1999-01-06 株式会社科薬 安定なポリミキシン系抗生物質水性溶液
DE3939346A1 (de) * 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
JPH078804B2 (ja) * 1990-08-28 1995-02-01 三菱化学株式会社 副腎皮質刺激ホルモン放出因子含有製剤
DE4126984A1 (de) 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, gut vertraeglichen arzneimitteln fuer infusions- oder injektionszwecke
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
JP3221120B2 (ja) * 1992-12-25 2001-10-22 ソニー株式会社 復号装置
US6288030B1 (en) * 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
JP3044333B2 (ja) 1994-06-10 2000-05-22 大日本スクリーン製造株式会社 減圧式基板処理槽の蓋開閉装置
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
GB9424902D0 (en) * 1994-12-09 1995-02-08 Cortecs Ltd Solubilisation Aids
PT814778E (pt) * 1995-03-10 2001-11-30 Roche Diagnostics Gmbh Formas de administracao farmaceuticas contendo polipeptidos sob a forma de microparticulas e processo para a sua preparacao
JP3170437B2 (ja) 1995-09-20 2001-05-28 株式会社日立製作所 不揮発性半導体多値記憶装置
TW518219B (en) * 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation

Also Published As

Publication number Publication date
JP3068033B2 (ja) 2000-07-24
US20040087507A1 (en) 2004-05-06
EP1712237A2 (de) 2006-10-18
JP2004196824A (ja) 2004-07-15
US6120761A (en) 2000-09-19
AU2407497A (en) 1997-11-19
JP4589018B2 (ja) 2010-12-01
EP1712237A3 (de) 2008-05-07
TWI240627B (en) 2005-10-01
US6627187B2 (en) 2003-09-30
JP3618633B2 (ja) 2005-02-09
EP0909564A4 (de) 2003-03-26
DE69736177T2 (de) 2007-05-16
EP1712237B1 (de) 2010-08-18
KR20040004414A (ko) 2004-01-13
US20010055582A1 (en) 2001-12-27
KR20000064995A (ko) 2000-11-06
KR100417031B1 (ko) 2004-07-19
US6277367B1 (en) 2001-08-21
ATE330622T1 (de) 2006-07-15
TW200300340A (en) 2003-06-01
AU722300B2 (en) 2000-07-27
ES2267140T3 (es) 2007-03-01
DE69739968D1 (de) 2010-09-30
DE69736177D1 (de) 2006-08-03
EP0909564B1 (de) 2006-06-21
US7011825B2 (en) 2006-03-14
TW518219B (en) 2003-01-21
JP2000302689A (ja) 2000-10-31
EP0909564A1 (de) 1999-04-21
JPH10182481A (ja) 1998-07-07
WO1997040850A1 (fr) 1997-11-06

Similar Documents

Publication Publication Date Title
DE69739968D1 (de) Erythropoietin-Lösungszubereitung, stabilisiert mit Leucin oder Glutaminsäure
EP1454138A4 (de) Immunocytokine mit modulierter selektivität
ATE229280T1 (de) Verbesserungen von kreatin-zusammensetzungen
DK0713529T3 (da) Vækst-/differentieringsfaktor af TGF-beta-familien
DK0929564T3 (da) Höjniveau-ekspression af proteiner
ATE533848T1 (de) Anwendung von glukose-transport-mutanten zur erzeugung von aromatischen stoffwechselverbindungen
MX353234B (es) Variantes de polipeptidos con función efectora alterada.
ATE286740T1 (de) Zyklische peptide mit breitspektrum antimikrobieller aktivität
DE60037347D1 (de) Kombinationen enthaltend cGMP-PDE5-hemmer.
CY1108688T1 (el) Μυκητοκτονα μειγματα στη βαση ενωσεων αμιδιου
DE3685793D1 (de) Ein aminosaeurepolymer enthaltende zusammensetzung mit verzoegerter abgabe.
DE3891417T1 (de) Stamm der bakterien escherichia coli bkiim b-3996, produziert von l-threonin
DK0513699T3 (da) Zinksalte af visse mercaptoforbindelser som antioxidanter til højtemperaturældning af termoplastiske elastomerer
DE60020943D1 (de) HYDANTOINASE-VARIANTEN MIT VERBESSERTEN EIGENSCHAFTEN UND IHRE ANWENDUNG ZUR PRODUKTION VON AMINOSäUREN
DE69312232D1 (de) Bpc-peptide, ihre herstellung und verwendung
CA2319094A1 (en) Antimicrobial peptides
DE69032102D1 (de) Stabilisierte impfstoffzusammensetzungen
PT882726E (pt) Carbazol-carboxamidas como agonistas 5-ht1f
TR200002101T2 (tr) Dondurulmuş gıda ürünü.
DE60013939D1 (de) Stereoselektive Transaminase, deren kodierende Gen und deren Verwendungen
DE59006688D1 (de) Substituierte Aminosäureamid-Derivate, deren Herstellung und Verwendung.
DE59203924D1 (de) Substituierte Aminosäureamid-Derivate deren Herstellung und Verwendung als Fungizide.
ATE355087T1 (de) Stabilisierung von radiopharmazeutischen zusammensetzungen mit einem hydrophilen thioether oder einem hydrophilen 6-hydroxy-chroman
DK38889A (da) Onkogen-indkodet polypeptid med vaekstfaktoraktivitet
DK0640608T3 (da) Mellemprodukter til syntese af cephalosporiner

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1712237

Country of ref document: EP